Telix Pharmaceuticals (NASDAQ:TLX) Given Outperform Rating at Wedbush

Telix Pharmaceuticals (NASDAQ:TLX)‘s stock had its “outperform” rating reiterated by equities research analysts at Wedbush in a research note issued to investors on Wednesday, Benzinga reports. They currently have a $22.00 price objective on the stock. Wedbush’s price target indicates a potential upside of 94.52% from the company’s previous close.

TLX has been the topic of several other reports. Royal Bank Of Canada upgraded shares of Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a research report on Monday. Citigroup reiterated a “buy” rating on shares of Telix Pharmaceuticals in a research report on Thursday, August 20th. Weiss Ratings upgraded shares of Telix Pharmaceuticals from a “sell (d)” rating to a “hold (c-)” rating in a research report on Friday, August 21st. Finally, HC Wainwright reiterated a “buy” rating and issued a $20.00 price target on shares of Telix Pharmaceuticals in a research report on Tuesday, September 15th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, Telix Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $20.50.

Telix Pharmaceuticals Stock Up 0.4%

Telix Pharmaceuticals stock traded up $0.04 during mid-day trading on Wednesday, reaching $11.31. The company had a trading volume of 830,214 shares, compared to its average volume of 220,945. Telix Pharmaceuticals has a 1 year low of $6.28 and a 1 year high of $13.11. The company has a current ratio of 2.01, a quick ratio of 1.85 and a debt-to-equity ratio of 1.16. The stock’s 50-day simple moving average is $11.33 and its 200-day simple moving average is $10.47.

Institutional Trading of Telix Pharmaceuticals

Hedge funds have recently bought and sold shares of the company. Lazard Asset Management LLC boosted its position in Telix Pharmaceuticals by 15.7% during the first quarter. Lazard Asset Management LLC now owns 289,917 shares of the company’s stock worth $2,775,000 after acquiring an additional 39,400 shares during the last quarter. Hennion & Walsh Asset Management Inc. acquired a new stake in Telix Pharmaceuticals during the second quarter worth approximately $1,731,000. Private Advisor Group LLC boosted its position in Telix Pharmaceuticals by 276.3% during the first quarter. Private Advisor Group LLC now owns 174,415 shares of the company’s stock worth $1,669,000 after acquiring an additional 128,070 shares during the last quarter. XY Capital Ltd boosted its position in Telix Pharmaceuticals by 468.0% during the second quarter. XY Capital Ltd now owns 71,291 shares of the company’s stock worth $822,000 after acquiring an additional 58,739 shares during the last quarter. Finally, Bank of America Corp DE boosted its position in Telix Pharmaceuticals by 523.8% during the first quarter. Bank of America Corp DE now owns 10,031 shares of the company’s stock worth $96,000 after acquiring an additional 8,423 shares during the last quarter.

Key Telix Pharmaceuticals News

Here are the key news stories impacting Telix Pharmaceuticals this week:

• Positive Sentiment: Analyst upgrade supports the shares: Bell Potter Securities upgraded Telix to Buy from Hold, adding to positive sentiment around the company’s growth outlook. Bell Potter upgrades Telix to Buy
• Positive Sentiment: Wedbush remains bullish: Wedbush reaffirmed its Outperform rating and set a $22 price target, implying substantial upside from recently reported trading levels. Wedbush reaffirms Telix Outperform rating
• Positive Sentiment: ITM acquisition expands strategic reach: Telix agreed to acquire Germany’s ITM Isotope Technologies Munich for up to $2.35 billion. The transaction includes $1.65 billion paid upfront, with a further $700 million contingent on regulatory approval and sales milestones. The acquisition is intended to secure isotope supply and broaden Telix’s radiopharmaceutical capabilities. Telix to acquire ITM
• Neutral Sentiment: Valuation is being reassessed: Coverage of the ITM transaction has put Telix’s valuation back in focus, with investors weighing the potential pipeline and supply benefits against the acquisition price and integration requirements. ITM deal shifts Telix valuation
• Neutral Sentiment: Short-interest data offers little signal: Reported short interest was zero shares as of September 24, producing a zero-day days-to-cover ratio. This may reflect incomplete or anomalous reporting rather than a meaningful change in investor positioning.

About Telix Pharmaceuticals

Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing radiopharmaceuticals for the diagnosis and treatment of cancer and other serious diseases. Its products use targeted molecules to deliver radioactive isotopes to specific tissues, supporting precision imaging and therapeutic applications.

The company’s commercial portfolio includes Illuccix, a gallium-68 radiolabeled prostate-specific membrane antigen (PSMA) imaging agent used with PET scans to help detect and manage prostate cancer.